LJL Biosystems, Inc (LJLB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LJL Biosystems, Inc (LJLB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: -Mad-Jon who wrote ()	2/22/2000 9:23:00 AM
From: -Mad-Jon	of 90

SmithKline Beecham Using LJL BioSystems' First FLARe System to Screen Difficult Compounds Successful Completion of Another Major Collaboration Milestone SUNNYVALE, Calif.--(BUSINESS WIRE)--Feb. 22, 2000--LJL BioSystems, Inc. (Nasdaq:LJLB - news) today announced the successful completion of another milestone in their collaboration with SmithKline Beecham (NYSE:SB - news) with the acceptance and delivery of the first system utilizing LJL's FLARe(TM) (Fluorescence Lifetime Assay Repertoire) technology. The system is already in use for screening compound libraries that are difficult to screen by other fluorescence methodologies. LJL's collaboration with SmithKline Beecham involves early access to LJL's advanced proprietary technologies for High Throughput Screening (HTS) and FLARe. FLARe is LJL's patented and patent pending instrumentation and reagent platform for addressing next generation solutions for critical drug discovery and genomics challenges.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next